abemaciclib - Profile

What are the generic sources for abemaciclib and what is the scope of freedom to operate?

Abemaciclib is the generic ingredient in one branded drug marketed by Eli Lilly And Co and is included in one NDA. There is one patent protecting this compound. Additional information is available in the individual branded drug profile pages.

Abemaciclib has fifty-two patent family members in forty-five countries.

There is one tentative approval for this compound.

Summary for abemaciclib

International Patents:	52
US Patents:	1
Tradenames:	1
Applicants:	1
NDAs:	1

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for abemaciclib

Constraining patent/regulatory exclusivity:

7,855,211

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Generic filers with tentative approvals for ABEMACICLIB

Applicant	Application No.	Strength	Dosage Form
		50MG	TABLET
		100MG	TABLET
		150MG	TABLET

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Paragraph IV (Patent) Challenges for ABEMACICLIB

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
VERZENIO	Tablets	abemaciclib	50 mg, 100 mg, 150 mg, 200 mg	208716	1	2026-03-23

US Patents and Regulatory Information for abemaciclib

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eli Lilly And Co	VERZENIO	abemaciclib	TABLET;ORAL	208716-001	Sep 28, 2017		RX	Yes	No	7,855,211		Y	Y
Eli Lilly And Co	VERZENIO	abemaciclib	TABLET;ORAL	208716-002	Sep 28, 2017		RX	Yes	No	7,855,211		Y	Y
Eli Lilly And Co	VERZENIO	abemaciclib	TABLET;ORAL	208716-003	Sep 28, 2017		RX	Yes	No	7,855,211		Y	Y
Eli Lilly And Co	VERZENIO	abemaciclib	TABLET;ORAL	208716-004	Sep 28, 2017		RX	Yes	Yes	7,855,211		Y	Y

EU/EMA Drug Approvals for abemaciclib

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
Eli Lilly Nederland B.V.	Verzenios	abemaciclib	EMEA/H/C/004302Early Breast CancerVerzenios in combination with endocrine therapy is indicated for the adjuvant treatment of adult patients with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative, node positive early breast cancer at high risk of recurrence (see section 5.1).In pre or perimenopausal women, aromatase inhibitor endocrine therapy should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.Advanced or Metastatic Breast CancerVerzenios is indicated for the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic breast cancer in combination with an aromatase inhibitor or fulvestrant as initial endocrine-based therapy, or in women who have received prior endocrine therapy.In pre- or perimenopausal women, the endocrine therapy should be combined with a LHRH agonist.	Authorised	no	no	no	2018-09-26

International Patents for abemaciclib

Country	Patent Number	Title	Estimated Expiration
Poland	2379528
Panama	8852901	INHIBIDORES DE PROTEINA CINASA
Taiwan	I429635
Japan	5417453
Tunisia	2011000293	PROTEIN KINASE INHIBITORS
Eurasian Patent Organization	018808

Supplementary Protection Certificates for abemaciclib

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2379528	C201930017	Spain		PRODUCT NAME: ABEMACICLIB O UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO; NATIONAL AUTHORISATION NUMBER: EU/1/18/1307; DATE OF AUTHORISATION: 20180927; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/18/1307; DATE OF FIRST AUTHORISATION IN EEA: 20180927
2379528	LUC00106	Luxembourg		PRODUCT NAME: ABEMACICLIB ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (VERZENIOS); AUTHORISATION NUMBER AND DATE: EU/1/18/1307 20181001
2379528	201940009	Slovenia		PRODUCT NAME: ABEMACICLIB; NATIONAL AUTHORISATION NUMBER: EU/1/18/1307; DATE OF NATIONAL AUTHORISATION: 20180927; AUTHORITY FOR NATIONAL AUTHORISATION: EU
2379528	132019000000037	Italy		PRODUCT NAME: ABEMACICLIB(VERZENIOS); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/18/1307, 20181001
2379528	19C1008	France		PRODUCT NAME: ABEMACICLIB; REGISTRATION NO/DATE: EU/1/18/1307 20181001
2379528	PA2019004	Lithuania		PRODUCT NAME: ABEMACIKLIBAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/18/1307 20180927

Abemaciclib: Investment Scenario, Market Dynamics, and Financial Trajectory

Last updated: February 3, 2026

---

Summary

Abemaciclib (marketed as Verzenio by Eli Lilly and Company) is an oral CDK4/6 inhibitor approved for the treatment of HR+/HER2- advanced or metastatic breast cancer. Since its FDA approval in 2017, it has become a significant product within oncology, with expansion into early-stage breast cancer and potential pipeline growth avenues. This analysis synthesizes the current investment landscape, competitive market dynamics, and projected financial trajectory for abemaciclib, incorporating recent data, market forecasts, regulatory trends, and strategic factors shaping its future.

---

What is the Current Market Position of Abemaciclib?

Parameter	Details
Approved Indications	HR+/HER2- metastatic breast cancer; adjuvant setting (pending approval)
FDA Approval Date	August 2017
Global Sales (2022)	~$1.4 billion (approximate, per IQVIA)
Market Share (CDK4/6 inhibitors)	~45% among CDK4/6 class (including palbociclib, ribociclib)
Main Competitors	Palbociclib (Ibrance), Ribociclib (Kisqali)

Product Adoption and Revenue Trends

Since launch, abemaciclib’s revenue has shown steady growth, driven by:

• Expanded indications for early-stage breast cancer (approved in 2021 in the U.S.)
• Favorable tolerability profile in certain patient subgroups
• Increasing adoption in treatment guidelines

In 2022, Lilly reported global net sales of Verzenio at approximately $1.4 billion, marking CAGR of ~20% from 2019 to 2022.

---

What Are Investment Drivers and Challenges?

Key Investment Drivers

Driver	Impact	Supporting Evidence
Expanding Indications	Extends market size, increases revenue potential	FDA approval for adjuvant breast cancer in 2021; ongoing trials
Market Penetration and Adoption	Growing share among oncology practitioners	Increasing prescribing rates in U.S. and Europe
Pipeline and Combination Therapy Development	Potential for broader applications, resistance management	Trials combining abemaciclib with immunotherapies, other agents
Pricing and Reimbursement Trends	Favorable in major markets; premium pricing possible	Managed care acceptance rising, differential pricing in emerging markets
Lilly’s Strategic Positioning	Strong R&D, marketing capabilities, diversified pipeline	Lilly’s broad oncology portfolio and manufacturing capacity

Primary Challenges

Challenge	Impact	Mitigation Strategies
Intense Competition	Market share consolidation among CDK4/6 inhibitors	Differentiation via efficacy, safety, combination regimens
Regulatory Hurdles & Approvals	Delays could hinder expansion	Early engagement with regulators, robust clinical evidence
Patent Expiry and Biosimilars	Erosion of exclusivity	Strategic patent filings, lifecycle management programs
Pricing Pressure	Limits profit margins	Value-based pricing, patient access programs

---

Market Dynamics: Competitive Landscape and Future Outlook

Market Size and Forecast

Parameter	2022 Estimate	2027 Projection	CAGR (2022–2027)
Global Oncology Market	~$175 billion[1]	~$240 billion[2]	~7.7%
CDK4/6 Inhibitors Market	~$4 billion[3]	~$9 billion	~17%
Abemaciclib Share within CDK4/6	~45% in 2022	~37-40% in 2027	Variable (market_maturation)

Key Market Opportunities

1. Early-Stage Breast Cancer Expansion

   • US FDA approval in 2021 for adjuvant setting; EMA approval pending
   • Potential to convert early-stage patients, doubling market size

2. Combination Regimens with Immunotherapy

   • Clinical trials—Phase 1/2—exploring combining abemaciclib with checkpoint inhibitors (e.g., pembrolizumab)
   • Possible to open new indications or improve outcomes, expanding market footprint

3. Emerging Markets and Price Segmentation

   • Growth in Asia-Pacific and Latin America owing to increased cancer prevalence and healthcare infrastructure investments
   • Strategic pricing policies to penetrate price-sensitive regions

4. Pipeline and Developmental Opportunities

   • Trials investigating abemaciclib in other cancers, such as non-small cell lung cancer (NSCLC) and ovarian cancer
   • Ongoing research might unlock further indications, diversifying income streams

---

Financial Trajectory and Revenue Forecast

Projection Assumptions

Parameter	Details
Pipeline Expansion	Launch of adjuvant, additional combinations (2024–2026)
Market Penetration Rate	Incremental growth of 5–10% annually in targeted sectors
Pricing Dynamics	Stable or modest increase in developed markets (~3%)
Patent Expiry & BiosCREASE	Patents expiring between 2027–2030, with lifecycle extensions planned

Projected Revenue (2023–2027)

Year	Estimated Revenue (USD billions)	Notes
2023	$1.6 billion	Continued growth, initial uptick in early-line use
2024	$1.9 billion	Gains from expanded indications, new markets
2025	$2.3 billion	Peak of initial pipeline impact
2026	$2.75 billion	Market saturation, slight plateauing
2027	$3.3 billion	Full integration into treatment paradigms

Note: Estimates based on compound growth from historical trends, incorporating new indications and pipeline developments.

---

Comparison with Competitors

Parameter	Abemaciclib (Verzenio)	Palbociclib (Ibrance)	Ribociclib (Kisqali)
FDA Approval Year	2017	2015	2017
Main Indications	HR+/HER2- metastatic, adjuvant	HR+/HER2- metastatic	HR+/HER2- metastatic, earlier approval in some markets
Market Share (2022)	45%	~40%	15%
Pricing (USD per month)	~$10,000	~$11,000	~$9,500
Distinctive Features	Oral, once-daily, better tolerability in certain groups	First-to-market, established efficacy	Cost-effective in some regions

Market Share Dynamics

Inhibitor	2022 Market Share	Growth Drivers
Abemaciclib	45%	Expanded indications, combination trials
Palbociclib	40%	Established presence, aggressive marketing
Ribociclib	15%	Cost benefits, fewer approvals in late-stage settings

---

Regulatory and Policy Environment

Region	Trends & Impact
United States	FDA fast track for adjuvant indication; CMS reimbursement policies support adoption
Europe	EMA approvals, nominal reimbursement constraints in some countries
China & Asia-Pacific	Growing approvals, government-led schemes to improve access
Policy Impacts	Price negotiations and formulary placements influence revenue trajectory

---

Deep-Dive Considerations for Investors

Factor	Implication
Pipeline Validation	Success in ongoing trials (e.g., combination with immunotherapy) can unlock multi-billion revenue streams
Regulatory Milestones	Approvals in new indications (e.g., early-stage breast cancer) forecast revenue expansion
Competitive Position	Maintaining differentiation—efficacy, safety, and dosing convenience—is crucial
Market Penetration	Accelerated adoption in emerging markets can improve revenues but requires strategic pricing and partnerships
Patent Cliff Management	Securing lifecycle extensions through patents, formulations, and combination patents to sustain revenue longer

---

Key Takeaways

• Market Expansion Potential: Abemaciclib's recent FDA approval for adjuvant breast cancer significantly broadens its total addressable market, with forecasts indicating a revenue increase to ~$3.3 billion by 2027.
• Pipeline and Combination Trials: The ongoing clinical trials exploring combination therapies and new indications could double or triple current revenue streams if successful.
• Competitive Positioning: While abemaciclib currently leads in market share among CDK4/6 inhibitors, competition remains fierce, and maintaining differentiation is vital.
• Pricing and Reimbursement Trends: Strategies tailored to diverse markets, especially emerging ones, are essential to unlock global growth.
• Regulatory and Patent Environment: Active management of patent life cycles and early regulatory engagement can prolong commercial viability.

---

FAQs

1. What are the primary factors influencing abemaciclib’s market growth?
   Expansion into early-stage breast cancer, combination therapies with immuno-oncology agents, regulatory approvals, and increasing adoption in emerging markets drive growth.

2. How does abemaciclib compare to its main competitors in efficacy and safety?
   Clinical trials suggest comparable efficacy with palbociclib and ribociclib, with some evidence indicating a better tolerability profile, especially regarding gastrointestinal side effects.

3. What are the risks associated with investing in abemaciclib?
   Competition, patent expirations, pricing pressures, regulatory delays, and pipeline failure pose significant risks.

4. What pipeline developments could impact abemaciclib’s financial trajectory?
   Trials of companion therapies, new indications in other cancer types, and combination regimens could expand its market footprint significantly.

5. When do patent protections for abemaciclib expire, and what is the impact on revenue?
   Patents typically expire around 2027–2030, after which biosimilars and generics could erode market share unless lifecycle strategies are implemented.

---

References

[1] IQVIA. (2022). Global Oncology Market Report.
[2] MarketWatch. (2023). Oncology Market Forecast.
[3] GlobalData. (2022). CDK4/6 Inhibitors Market Analysis.

---

Note: All projections and market figures are estimations based on current trends and publicly available data. Actual results may vary.